|1.||Duan, Chenfan: 1 article (07/2015)|
|2.||Chai, Hongyan: 1 article (07/2015)|
|3.||Li, Ying: 1 article (07/2015)|
|4.||Chen, Honglei: 1 article (07/2015)|
|5.||Chen, Xuewei: 1 article (07/2015)|
|6.||Qin, Tian: 1 article (07/2015)|
|7.||Yue, Jiang: 1 article (07/2015)|
|8.||Tang, Tian: 1 article (07/2015)|
|9.||Wang, Chenlong: 1 article (07/2015)|
|10.||Yang, Jing: 1 article (07/2015)|
|1.||Amnesia (Dissociative Amnesia)
04/22/1996 - "Intracerebroventricularly administered S(-)-eticlopride (0.01-1 microgram) also inhibited the emesis induced by s.c. "
11/23/2001 - "S(-)-eticlopride (10 microg/kg, i.c.v.) did not inhibit emesis induced by cisplatin. "
04/22/1996 - "S(-)-Eticlopride, which has a high affinity for the dopamine D3 receptor, antagonized R(+)-7-OH-DPAT (0.3 mg/kg, s.c.)-induced emesis (ID50 1.4 micrograms/kg, s.c.). "
01/01/1995 - "The emesis induced by R(+)-7-OH-DPAT (0.3 mg/kg, s.c.) was inhibited by S(-)-eticlopride (0.01-0.1 mg/kg, s.c.), a potent D2 and D3 receptor antagonist but not by SCH-23390 (1 mg/kg, s.c.), a selective D1 receptor antagonist or clozapine (1 mg/kg, s.c.), a D4 receptor antagonist. "
04/01/2001 - "Neither naltrexone nor eticlopride affected formalin pain scores. "
06/01/2007 - "Attenuation of pain-related responses induced by striatal administration of quinpirole was reversed by intrathecal administration of a dopamine D(2) receptor antagonist (eticlopride) or a non-selective 5-HT receptor antagonist (methysergide), but not by an alpha(2)-adrenoceptor antagonist (atipamezole). "
06/01/2011 - "DR2 was responsible for the inhibitory effects of dopamine on tumor growth and microvessel density as well as the stimulatory effect on apoptosis, as the DR2 antagonist eticlopride reversed these effects. "
07/15/2015 - "Conversely, an antagonist of dopamine receptor 2 (DR2) (eticlopride) but not DR1 (butaclamol) abrogated DA-induced tumor regression and vascular normalization. "
12/01/2000 - "Reinstatement of hyperthermia to alphaMT- or eticlopride-pretreated rats partially restored the METH-induced decrease in DAT activity. "
05/01/2005 - "The dissociation of methamphetamine-induced striatal dopamine reduction and hyperthermia seen after eticlopride pretreatment suggests a dopamine D2 receptor mechanism in mediating methamphetamine-induced dopamine depletion. "
|2.||P-30 composite resin (P 30)
|7.||Dopamine D2 Receptors (Dopamine D2 Receptor)